...
首页> 外文期刊>Oncology letters >Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors
【24h】

Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors

机译:PLK1信号通路基因在胃肠道间质瘤中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

In previous studies by the authors, aurora kinase A (AURKA) was demonstrated as an independent poor prognostic marker for the recurrence of localized gastrointestinal stromal tumors (GISTs) and for the progression of advanced GISTs. In the present study, the prognostic effect of genes involved in cell cycle regulation in GISTs was further examined. Leading edge analysis in gene set enrichment analysis was used to identify the most common genes in the top 10 enriched gene sets of high-risk patients with GISTs in a Japanese study. The obtained gene list was uploaded to the Pathway Interaction Database to search for critical pathways. Selected genes within the pathway were subsequently verified through immunohistochemistry (IHC) in another cohort of patients. A total of 5 genes in PLK1 signaling events,' namely AURKA, polo-like kinase 1 (PLK1), cell division cycle 25C (CDC25C), budding uninhibited by benzimidazoles (BUB1), and targeting protein for Xklp2 (TPX2), were identified for subsequent study. Among the Japanese cohort, all 5 genes, except BUB1, were significant prognostic factors for poor recurrence-free survival (RFS). Among 141 patients enrolled for the IHC study, all 5 genes exhibited variable expression patterns. In the association study, only AURKA exhibited significant overexpression in non-gastric tumors. Although all 5 genes were considered as risk factors for poor RFS based on a univariate analysis, only the mitotic count and expression levels of CDC25C, BUB1, and TPX2 retained prognostic effects in the multivariate analysis. The PLK1 signaling pathway is crucial in the disease progression of GISTs. Genes within this pathway may serve as predictive markers for adjuvant therapy.
机译:在先前作者的研究中,Aurora激酶A(Aurka)被证明为局部胃肠内脏基质肿瘤(GISTS)复发的独立差的预后标志物和先进的GIST的进展。在本研究中,进一步研究了参与细胞周期调节的基因的预后作用。基因设定富集分析中的前沿分析用于鉴定日本研究中的11名高危患者的高风险患者最常见的基因。将获得的基因列表上载到路径交互数据库以寻找关键途径。随后通过在另一种患者队列中的免疫组织化学(IHC)核实途径内的所选基因。鉴定了PLK1信号传导事件中总共5个基因,'Aurka,Polo样激酶1(PLK1),细胞分裂周期25c(CDC25c),芽孢甲酰胺唑(bub1),芽孢芽,靶向XKLP2(TPX2)靶向蛋白质随后的研究。在日本队列中,除Bub1之外,所有5个基因都是无缺乏复发存活率(RFS)的显着预后因素。在注册IHC研究的141名患者中,所有5个基因都表现出可变的表达模式。在该协会研究中,只有Aurka在非胃肿瘤中表现出显着的过表达。尽管基于单变量分析,但所有5个基因被认为是差的RFS的危险因素,但仅仅是CDC25C,BUB1和TPX2在多变量分析中保留了预后作用的有丝分裂计数和表达水平。 PLK1信号传导途径对于GIST的疾病进展至关重要。该途径内的基因可用作佐剂治疗的预测标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号